01 1Edoxaban
02 11Lixiana
03 4Savaysa
Main Therapeutic Indication : Hematology
Currency : USD
2020 Revenue in Millions : 28
2019 Revenue in Millions : 25
Growth (%) : 15
Main Therapeutic Indication : Hematology
Currency : USD
2020 Revenue in Millions : 707
2019 Revenue in Millions : 745
Growth (%) : -5
Main Therapeutic Indication : Hematology
Currency : USD
2020 Revenue in Millions : 676
2019 Revenue in Millions : 516
Growth (%) : 31
Main Therapeutic Indication : Hematology
Currency : USD
2021 Revenue in Millions : 743
2020 Revenue in Millions : 703
Growth (%) : 14
Main Therapeutic Indication : Hematology
Currency : USD
2021 Revenue in Millions : 802
2020 Revenue in Millions : 672
Growth (%) : 29
Main Therapeutic Indication : Hematology
Currency : USD
2022 Revenue in Millions : 849
2021 Revenue in Millions : 802
Growth (%) : 6
Main Therapeutic Indication : Hematology
Currency : USD
2022 Revenue in Millions : 781
2021 Revenue in Millions : 743
Growth (%) : 5
Main Therapeutic Indication : Hematology
Currency : USD
2023 Revenue in Millions : 926
2022 Revenue in Millions : 849
Growth (%) : 24
Main Therapeutic Indication : Hematology
Currency : USD
2023 Revenue in Millions : 780
2022 Revenue in Millions : 781
Growth (%) : 13
Main Therapeutic Indication : Blood Disorders
Currency : USD
2017 Revenue in Millions : 278
2016 Revenue in Millions : 617
Growth (%) : -55
